Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study of LJP 394 (Abetimus Sodium) in Lupus Patients
This study has been withdrawn prior to recruitment.
Sponsored by: La Jolla Pharmaceutical Company
Information provided by: La Jolla Pharmaceutical Company
ClinicalTrials.gov Identifier: NCT00390091
  Purpose

The primary purpose of this study is to assess the safety and pharmacodynamic effect of LJP 394 at doses of 100 mg, 300 mg and 900 mg on anti-dsDNA antibody levels in patients with SLE.


Condition Intervention Phase
Systemic Lupus Erythematosus
 Drug: abetimus sodium (LJP 394)
 Phase II

MedlinePlus related topics: Dietary Sodium Lupus
Drug Information available for: Abetimus Abetimus sodium
U.S. FDA Resources
Study Type: Interventional
Study Design: Diagnostic, Randomized, Single Blind, Dose Comparison, Parallel Assignment, Pharmacokinetics/Dynamics Study
Official Title: A Randomized, Double-Blind Study to Evaluate the Safety, Pharmacokinetic and Pharmacodynamic Effects of Abetimus Sodium in Patients With Systemic Lupus Erythematosus (SLE)

Further study details as provided by La Jolla Pharmaceutical Company:

Primary Outcome Measures:
  • The assessment of the safety and pharmacodynamic effect of abetimus sodium at
  • doses of 100mg, 300mg, and 900mg in reducing the anti-dsDNA antibody levels in
  • patients with SLE will be based on laboratory data from the central laboratory
  • and confirmed by supporting data. The pharmacodynamic effic will be assessed
  • using historical placebo effect as a control.

Estimated Enrollment: 45
Study Start Date: September 2006
Detailed Description:

STUDY NOW INCORPORATED INTO PHASE 3 STUDY NCT00089804.

  Eligibility

Ages Eligible for Study:   12 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females between 12 and 70 years old.
  • Diagnosis of Systemic Lupus Erythematosus (SLE)
  • Females must be non-pregnant and non-lactating. Females must agree to use adequate birth control methods during the course of the study.
  • Ability to have weekly intravenous (IV) administration of study drug.

Exclusion Criteria:

  • Prior exposure to abetimus sodium within 6 months prior to screening.
  • Patients not on stable medications for 30 days prior to screening.
  • Patients with acute or chronic infections.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00390091

Locations
United States, California
Wallace Rheumatic Study Center
Los Angeles, California, United States, 90048
United States, Pennsylvania
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
Sponsors and Collaborators
La Jolla Pharmaceutical Company
Investigators
Study Chair: Matthew D Linnik, PhD La Jolla Pharmaceutical Company
  More Information

Sponsor's website  This link exits the ClinicalTrials.gov site
STUDY NOW INCORPORATED INTO PHASE 3 STUDY NCT00089804  This link exits the ClinicalTrials.gov site

Study ID Numbers: LJP 394-90-16
Study First Received: October 17, 2006
Last Updated: February 5, 2007
ClinicalTrials.gov Identifier: NCT00390091  
Health Authority: United States: Food and Drug Administration

Keywords provided by La Jolla Pharmaceutical Company:
Lupus
Nephritis
Kidney
 SLE
Systemic Lupus Erythematosus
Nephritis, Lupus

Study placed in the following topic categories:
Autoimmune Diseases
Lupus Erythematosus, Systemic
Nephritis
Connective Tissue Diseases

Additional relevant MeSH terms:
Immune System Diseases

ClinicalTrials.gov processed this record on January 15, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services